Pan, Minggui <br/><br/>
CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.  [electronic resource] 

 -  Nature clinical practice. Oncology  Oct 2007 
 - 603-7 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1743-4262 
<br/><br/><label>Standard No.: </label>10.1038/ncponc0931  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents--therapeutic use<br/>Brain Neoplasms--drug therapy<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Humans<br/>Lung Neoplasms--genetics<br/>Male<br/>Mutation<br/>Protein Kinase Inhibitors--therapeutic use<br/>Quinazolines--therapeutic use